ADAM10 overexpression in human non-small cell lung cancer correlates with cell migration and invasion through the activation of the Notch1 signaling pathway

Oncology Reports

Volumn 28, Issue 5, 2012, Pages 1709-1718

  Guo, Jianli ^a   He, Lei ^a   Yuan, Ping ^a   Wang, Peng ^a   Lu, Yanjun ^a   Tong, Fangli ^a   Wang, Yu ^a   Yin, Yanhua ^a   Tian, Jun ^a   Sun, Jun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

A disintegrin and metalloproteinase 10; Metastasis; Non small cell lung cancer; Notch1

Indexed keywords

ADAM10 ENDOPEPTIDASE; BETA CATENIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOTCH1 RECEPTOR; SHORT HAIRPIN RNA;

ADULT; ARTICLE; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOWN REGULATION; ENZYME REPRESSION; FEMALE; GENE SILENCING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TUMOR VOLUME; UPREGULATION;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; DIPEPTIDES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; RECEPTOR, NOTCH1; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84866443276     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2003     Document Type: Article

References (41)

1. Wu X, Piper-Hunter MG, Crawford M, Nuovo GJ, Marsh CB, Otterson GA and Nana-Sinkam SP: MicroRNAs in the pathogenesis of lung cancer. J Thorac Oncol 4: 1028-1034, 2009.
2. Ramalingam S and Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: recent advances and future directions. Oncologist 15: 5-13, 2008.
3. Curran WJ Jr: Treatment of locally advanced non-small cell lung cancer: what we have and have not learned over the past decade. Semin Oncol 32: S2-S5, 2005.
4. Edwards DR, Handsley MM and Pennington CJ: The ADAM metalloproteinases. Mol Aspects Med 29: 258-289, 2008.
5. Duffy MJ, McKiernan E, O'Donovan N and McGowan PM: Role of ADAMs in cancer formation and progression. Clin Cancer Res 15: 1140-1144, 2009.
6. Saftig P and Reissb K: The 'A Disintegrin and metalloproteases' ADAM10 and ADAM17: novel drug targets with therapeutic potential? Eur J Cell Biol 90: 527-535, 2011.
7. Shintani Y, Higashiyama S and Ohta M, et al: Overexpression of ADAM9 in non-small cell lung cancer. Cancer Res 64: 4190-4196, 2004.
8. Tsai WC, Hsu PW, Lai TC, et al: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology 49: 1571-1582, 2009.
9. Gaida MM, Haag N, Günther F, Tschaharganeh DF, Schirmacher P, Friess H, Giese NA, Schmidt J and Wente MN: Expression of A disintegrin and metalloprotease 10 in pancreatic carcinoma. Int J Mol Med 26: 281-288, 2010.
10. Crawford HC, Dempsey PJ, Brown G, Adam L and Moss ML: ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des 15: 2288-2299, 2009.
11. Ko SY, Lin SC, Wong YK, Liu CJ, Chang KW and Liu TY: Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 245: 33-43, 2007.
12. Fogel M, Gutwein P and Mechtersheimer S, et al: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. Lancet 362: 869-875, 2003. (Pubitemid 37130096)
13. Lee SB, Schramme A and Doberstein K, et al: ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol 130: 763-773, 2010.
14. Zhou BB, Peyton M and He B, et al: Targeting ADAM-mediated ligand c leavage t o i nhibit H ER3 a nd E GFR p athways i n non-small cell lung cancer. Cancer Cell 10: 39-50, 2006. (Pubitemid 44018087)
15. Galluzzo P and Bochetta M: Notch signaling in lung cancer. Expert Rev Anticancer Ther 11: 533-540, 2011.
16. López-Malpartida AV, Ludeña MD, Varela G and García Pichel J: Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas. Lung Cancer 65: 25-33, 2009.
17. Pelosi G, Scarpa A, Puppa G, et al: Alteration of the E-cadherin/ β-catenin cell adhesion system is common in pulmonary neuroendocrine tumors and is an independent predictor of lymph node metastasis in atypical carcinoids. Cancer 103: 1154-1164, 2005. (Pubitemid 40328085)
18. Lai EC: Notch signaling: control of cell communication and cell fate. Development 131: 965-973, 2004.
19. Yang Y, Ahn YH, Gibbons DL, et al: The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200- dependent pathway in mice. J Clin Invest 121: 1373-1385, 2011.
20. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP and Dang TP: γ-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res 67: 8051-8057, 2007. (Pubitemid 47395139)
21. Chen Y, Li D, Liu H, et al: Notch-1 signaling facilitates survivin expression in human non-small cell lung cancer cells. Cancer Biol Ther 11: 14-21, 2011.
22. Ji X, Wang Z, Geamanu A, Sarkar FH and Gupta SV: Inhibition of cell growth and induction of apoptosis in non-small cell lung cancer c ells by d elta-tocotrienol i s a ssociated w ith N otch-1 down-regulation. J Cell Biochem 112: 2773-2783, 2011.
23. Westhoff B, Colaluca IN, D'Ario G, et al: Alterations of the Notch pathway in lung cancer. Proc Natl Acad Sci USA 106: 22293-22298, 2009.
24. Donnem T, Andersen S, Al-Shibli K, Al-Saad S, Busund LT and Bremnes RM: Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer. Cancer 116: 5676-5685, 2010.
25. Hartmann D, de Strooper B and Serneels L, et al: The disintegrin/ metalloprotease ADAM 10 is essential for Notch signalling but not for α-secretase activity in fibroblasts. Hum Mol Genet 11: 2615-2624, 2002. (Pubitemid 35174691)
26. Miele L: Notch signaling. Clin Cancer Res 12: 1074-1079, 2006.
27. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T and Ben-Ze'ev A: L1, a novel target of β-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. J Cell Biol 168: 633-642, 2005. (Pubitemid 40271028)
28. Xu Q, Liu X, Chen W and Zhang Z: Inhibiting adenoid cystic carcinoma cells growth and metastasis by blocking the expression of ADAM 10 using RNA interference. J Transl Med 8: 136-146, 2010.
29. Grabher C, von Boehmer H and Look AT: Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukaemia. Nat Rev Cancer 6: 347-359, 2006.
30. Pang RT, Leung CO, Ye TM, et al: MicroRNA-34a suppresses invasion through downregulation of Notch1 and Jagged1 in cervical carcinoma and choriocarcinoma cells. Carcinogenesis 31: 1037-1044, 2010.
31. Nam DH, Jeon HM, Kim S, et al: Activation of Notch signaling in a xenograft model of brain metastasis. Clin Cancer Res 14: 4059-4066, 2008.
32. Wang Z, Banerjee S, Li Y, et al: Down-regulation of Notch-1 inhibits invasion by inactivation of nuclear factor-κB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer. Cancer Res 66: 2778-2784, 2006.
33. Sullivan JP, Spinola M, Dodge M, et al: Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70: 9937-9948, 2010.
34. van Tetering G, van Diest P, Verlaan I, van der Wall E, Kopan R and Vooijs M: Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. J Biol Chem 284: 31018-31027, 2009.
35. Brou C, Logeat F, Gupta N, et al: A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell 5: 207-216, 2000. (Pubitemid 30628080)
36. Bozkulak EC and Weinmaster G: Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling. Mol Cell Biol 29: 5679-5695, 2009.
37. Xie M, Zhang L, He CS, et al: Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem 113: 1501-1513, 2012.
38. McGowan PM, Simedrea C, Ribot EJ, et al: Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9: 834-844, 2011.
39. Bolós V, Blanco M, Medina V, Aparicio G, Díaz-Prado S and Grande E: Notch signaling in cancer stem cells. Clin Transl Oncol 11: 11-19, 2009.
40. Pannuti A, Foreman K, Rizzo P, Osipo C, Golde T, Osborne B and Miele L: Targeting Notch to target cancer stem cells. Clin Cancer Res 16: 3141-3152, 2010.
41. Barten DM, Meredith JE Jr, Zaczek R, Houston JG and Albright CF: Gamma-secretase inhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 7: 87-97, 2006.